1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Xylometazoline and Hyaluronic Acid Nasal Spray

Trade Name: OLYNTH HA
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as decongestant, bronchodilator, vasoconstrictor

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylometazoline hydrochloride</td>
<td>1218-35-5</td>
<td>214-936-4</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Glycerin, USP</td>
<td>56-81-5</td>
<td>200-289-5</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyaluronic Acid Sodium</td>
<td>9004-61-9</td>
<td>232-678-0</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Sodium dihydrogen phosphate dihydrate</td>
<td>13472-35-0</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>*</td>
</tr>
<tr>
<td>Sorbitol syrup</td>
<td>68425-17-2</td>
<td>270-337-8</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>*</td>
</tr>
<tr>
<td>Deionized water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Colorless liquid

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Harmful if swallowed . Harmful if inhaled . May cause irritation (based on components).

Long Term: May cause effects on cardiovascular system, central nervous system, respiratory system.

Known Clinical Effects: Clinical use may cause effect on the cardiovascular system, central nervous system, respiratory system local irritation.

EU Indication of danger: Not classified
Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Use appropriate ventilation. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Glycerin, USP
ENGINEERING CONTROLS: Engineering controls should be used as the primary means to control exposures.

PERSONAL PROTECTIVE EQUIPMENT:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: Not required for the normal use of this product. Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

9. PHYSICAL AND CHEMICAL PROPERTIES:

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Liquid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

| Color: | Colorless |
| Molecular Weight: | Mixture |

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride
- Rat Oral LD50 3000 mg/kg
- Mouse Oral LD 50 4000 mg/kg

Xylometazoline hydrochloride
- Rat Oral LD50 122 mg/kg
- Rat Inhalation LC50/4h >0.47 <1.08 mg/L

Glycerin, USP
- Mouse Oral LD50 4090 mg/kg
- Rat Oral LD50 12.6 g/kg
- Rabbit Dermal LD50 > 10 g/kg
- Rat Inhalation LC50 1hr > 570 mg/m³
Material Name: Xylometazoline and Hyaluronic Acid Nasal Spray
Revision date: 05-Jan-2007

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride
Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Sodium phosphate, dibasic
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Xylometazoline hydrochloride
Skin Irritation Rabbit Non-irritating

Glycerin, USP
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium chloride
10 Day(s) Rat Oral 12500 mg/kg LOAEL Kidney, Ureter, Bladder

Xylometazoline hydrochloride
3 Month(s) Rat Oral 6 mg/kg/day NOAEL Cardiovascular system
3 Month(s) Dog Oral 1 mg/kg/day LOAEL Cardiovascular system

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Xylometazoline hydrochloride
Bacterial Mutagenicity (Ames) Bacteria Negative
Micronucleus Mouse Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. The environmental characteristics of this material have not been fully evaluated.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP
Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L
Daphnia Magna (Water Flea) EC50 24 Hours >500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label: Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class: None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Xylometazoline hydrochloride
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS List: 214-936-4

Hyaluronic Acid Sodium
- Inventory - United States TSCA - Sect. 8(b): XU
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS List: 232-678-0

Sodium dihydrogen phosphate dihydrate
- Australia (AICS): Present

Sodium chloride
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS List: 231-598-3

Sorbitol syrup
- Inventory - United States TSCA - Sect. 8(b): Present
16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet